Pantoprazole Tad

Pantoprazole, the active ingredient in Pantoprazole Tad, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat gastro‑reflux conditions such as erosive oesophageal disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazole Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton‑pump inhibitor that addresses acid‑related disorders of the gastrointestinal tract.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Erosive oesophagitis: supports mucosal healing and symptom relief. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: inflammation of kidney interstitium. - Severe hypersensitivity: rash, angio‑edema or anaphylaxis. - Osteoporosis‑related fractures: increased risk with long‑term use. - Vitamin B12 deficiency: reduced absorption with prolonged therapy. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing Pantoprazole, clinicians should consider several safety aspects.

- Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential for altered absorption of drugs requiring gastric acidity. - Monitor long‑term use: evaluate risk of bone fracture and nutrient deficiencies. - Pregnancy and lactation: use only if clearly needed after risk‑benefit analysis. - Contra‑indications: avoid in patients with known hypersensitivity to pantoprazole or other PPIs. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH. - Atazanavir and other protease inhibitors: markedly decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, potentially increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values; monitor coagulation status. - Methotrexate: increased serum levels, especially at high doses. - Digoxin: modest increase in serum concentration; observe for toxicity signs.